Form 4: Bio-Rad Laboratories Executive Colleen Corey Reports Stock Option Grant

Sentiment:

SEC Form 4 Filing


EVP of Global Human Resources at Bio-Rad Laboratories, Colleen Corey, reports the acquisition of stock options.

Summary

  • On March 8, 2024, Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, acquired 2,357 non-qualified stock options.
  • The exercise price of these options is $343.76.
  • The options vest over four years, at a rate of 25% per year on the anniversary of the grant date.
  • The expiration date for these options is March 8, 2034.
  • Following the transaction, Corey directly owns 2,357 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.

Positives

  • The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and life sciences industries, used to attract and retain talent and align their interests with shareholder value.

Stakeholder Impact

  • The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates

DateDescription
03/08/2024Date of stock option grant and transaction.
03/08/2034Expiration date of the stock options.
03/11/2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.